Wheeze is an unreliable endpoint for bronchial methacholine challenges in preschool children
- PMID: 35470941
- PMCID: PMC9325539
- DOI: 10.1111/pai.13767
Wheeze is an unreliable endpoint for bronchial methacholine challenges in preschool children
Abstract
Background: Onset of wheeze is the endpoint often used in the determination of a positive bronchial challenge test (BCT) in young children who cannot perform spirometry. We sought to assess several clinical endpoints at the time of a positive BCT in young children with recurrent wheeze compared to findings in school-aged children with asthma.
Methods: Positive BCT was defined in: (1) preschool children (n = 22) as either persistent cough, wheeze, fall in oxygen saturation (SpO2 ) of ≥5%, or ≥50% increase in respiratory rate (RR) from baseline; and (2) school-aged children (n = 22) as the concentration of methacholine (MCh) required to elicit a 20% decline in FEV1 (PC20 ).
Results: All preschool children (mean age 3.4 years) had a positive BCT (median provocative MCh concentration 1.25 mg/ml [IQR, 0.62, 1.25]). Twenty (91%) school-aged children (mean age 11.3 years) had a positive BCT (median PC20 1.25 mg/ml [IQR, 0.55, 2.5]). At the time of the positive BCT, the mean fall in SpO2 (6.9% vs. 3.8%; p = .001) and the mean % increase in RR (61% vs. 22%; p < .001) were greater among preschool-aged than among school-aged children. A minority of children developed wheeze at time of positive BCT (23% preschool- vs. 15% school-aged children; p = .5).
Conclusions: The use of wheeze as an endpoint for BCT in preschool children is unreliable, as it rarely occurs. The use of clinical endpoints, such as ≥25% increase in RR or fall in SpO2 of ≥3%, captured all of our positive BCT in preschool children, while minimizing undue respiratory distress.
Keywords: asthma; bronchial hyper-responsiveness; lung function; methacholine challenge; preschool children; spirometry; wheezing.
© 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Conflict of interest statement
Dr Spahn is currently employed by AstraZeneca. This study was designed, implemented, funded, and written before his employment with AstraZeneca. AstraZeneca had no involvement in any phase of this study. The remaining authors have no conflict of interest to report.
Figures
References
-
- Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. N Engl J Med. 1995;332:133‐138. - PubMed
-
- Illi S, Von Mutius E, Niggemann B, Gruber C, Wahn U, on behalf of the Multicentre Allergy Study . Perennial allergen sensitization early in life and chronic asthma in children: a birth cohort study. Lancet. 2006;368:763‐770. - PubMed
-
- Spahn JD, Covar R. Clinical assessment of asthma progression in children and adults. J Allergy Clin Immunol. 2008;121:548‐557. - PubMed
-
- Palmer LJ, Rye PJ, Gibson NA, Burton PR, Landau LI, LeSouef PN. Airways responsiveness in early infancy predicts asthma, lung function and respiratory symptoms of school age. Am J Respir Crit Care Med. 2001;163:37‐42. - PubMed
-
- Avital A, Noviski N, Bar‐Yishay E, Springer C, Levy M, Godfrey S. Nonspecific bronchial reactivity in asthmatic children depends on severity but not on age. Am Rev Respir Dis. 1991;144:36‐38. - PubMed
